Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

Galsky MD, Gschwend JE, Milowsky MI, et al. Ann Oncol. 2025